Anne Ehret1, Victoria Naomi Bark1, Anne Mondal1, Tanja Natascha Fehm1, Monika Hampl2. 1. Department of Obstetrics and Gynecology, University Hospital of Duesseldorf, Duesseldorf, Germany. 2. Department of Obstetrics and Gynecology, University Hospital of Duesseldorf, Duesseldorf, Germany. hampl@med.uni-duesseldorf.de.
Abstract
BACKGROUND/ PURPOSE: The incidence and clinical course of high-grade cervical intraepithelial lesions (CIN 2/3) are age dependent. In CIN 3, the recommended treatment is conization, which increases the risk of cervical insufficiency or premature deliveries. But data concerning spontaneous regression of CIN 3 are rare. METHODS: Between 2007 and 2017, we identified 156 women under the age of 25 with CIN 2 (23%) or CIN 3 (77%), who had a consultation and were treated at the Colposcopy Unit, Hospital of Düsseldorf, Germany. This is a retrospective cohort study. These patients had colposcopical follow-ups every 4-6 months. Moreover, we analyzed various parameters to predict regression of cervical lesions in this age group. RESULTS: Patients diagnosed with CIN 2 showed regression in 88% (n = 30) and women with CIN 3 had a regression rate of 29% (n = 34). Complete regression was observed in 86.7% of CIN 2 and 47.1% of CIN3. Mean time to regression was 21 M (months) [2-70 M]. 70.9% of the patients were treated by surgery (LEEP) after persistence or progression. We identified several predictors for regression of CIN 2/3 in young women: the regression rate of CIN2 is significantly higher than CIN 3 (p < 0.001). Clearance of HPV infections had significantly higher rates of regression compared to persisting HPV infections (p < 0.001). HPV-vaccinated women showed significantly higher regression rates (p = 0.009). CONCLUSIONS: These data show that an expectative close follow-up in women with CIN 3 younger than 25 is possible with regression rates of 29% also for CIN 3. Especially in women who were HPV vaccinated and those who cleared their HPV infection. A frequent colposcopical follow-up every 3-4 months is important for CIN 3 and every 6 months for CIN 2.
BACKGROUND/ PURPOSE: The incidence and clinical course of high-grade cervical intraepithelial lesions (CIN 2/3) are age dependent. In CIN 3, the recommended treatment is conization, which increases the risk of cervical insufficiency or premature deliveries. But data concerning spontaneous regression of CIN 3 are rare. METHODS: Between 2007 and 2017, we identified 156 women under the age of 25 with CIN 2 (23%) or CIN 3 (77%), who had a consultation and were treated at the Colposcopy Unit, Hospital of Düsseldorf, Germany. This is a retrospective cohort study. These patients had colposcopical follow-ups every 4-6 months. Moreover, we analyzed various parameters to predict regression of cervical lesions in this age group. RESULTS: Patients diagnosed with CIN 2 showed regression in 88% (n = 30) and women with CIN 3 had a regression rate of 29% (n = 34). Complete regression was observed in 86.7% of CIN 2 and 47.1% of CIN3. Mean time to regression was 21 M (months) [2-70 M]. 70.9% of the patients were treated by surgery (LEEP) after persistence or progression. We identified several predictors for regression of CIN 2/3 in young women: the regression rate of CIN2 is significantly higher than CIN 3 (p < 0.001). Clearance of HPV infections had significantly higher rates of regression compared to persisting HPV infections (p < 0.001). HPV-vaccinated women showed significantly higher regression rates (p = 0.009). CONCLUSIONS: These data show that an expectative close follow-up in women with CIN 3 younger than 25 is possible with regression rates of 29% also for CIN 3. Especially in women who were HPV vaccinated and those who cleared their HPV infection. A frequent colposcopical follow-up every 3-4 months is important for CIN 3 and every 6 months for CIN 2.
Authors: Kari Syrjänen; Irena Shabalova; Nicolay Petrovichev; Vladimir Kozachenko; Tatjana Zakharova; Julia Pajanidi; Jurij Podistov; Galina Chemeris; Larisa Sozaeva; Elena Lipova; Irena Tsidaeva; Olga Ivanchenko; Alla Pshepurko; Sergej Zakharenko; Raisa Nerovjna; Ludmila Kljukina; Oksana Erokhina; Marina Branovskaja; Maritta Nikitina; Valerija Grunberga; Alexandr Grunberg; Anna Juschenko; Rosa Santopietro; Marcella Cintorino; Piero Tosi; Stina Syrjanen Journal: Anticancer Res Date: 2006 Nov-Dec Impact factor: 2.480
Authors: Peter Hillemanns; Klaus Friese; Christian Dannecker; Stefanie Klug; Ulrike Seifert; Thomas Iftner; Juliane Hädicke; Thomas Löning; Lars Horn; Dietmar Schmidt; Hans Ikenberg; Manfred Steiner; Ulrich Freitag; Uwe Siebert; Gaby Sroczynski; Willi Sauerbrei; Matthias W Beckmann; Marion Gebhardt; Michael Friedrich; Karsten Münstedt; Achim Schneider; Andreas Kaufmann; K Ulrich Petry; Axel P A Schäfer; Michael Pawlita; Joachim Weis; Anja Mehnert; Mathias Fehr; Christoph Grimm; Olaf Reich; Marc Arbyn; Jos Kleijnen; Simone Wesselmann; Monika Nothacker; Markus Follmann; Thomas Langer; Matthias Jentschke Journal: Geburtshilfe Frauenheilkd Date: 2019-02-18 Impact factor: 2.915